Get started
Author

X.-C. Zhang

Observed names: X-C. Zhang, Xiaohui Zhang3
ORCID: 0000-0001-7762-3167
Observed ORCID: 0000-0001-7762-3167
OpenAlex ID: A5081972002
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial
2014 · Q. Zhou, Y. Cheng, et al. · Annals of Oncology · 67
PDF
The high-risk factors of different severities of bronchopulmonary dysplasia (BPD) based on the national institute of child health and human development (NICHD) diagnosis criteria in 2018
2021 · Minqiao Jian1,2, Shaoru He1,2, et al. · Jornal Brasileiro de Pneumologia · 6
PDF
Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
2017 · R.-L. Chen, H.-J. Chen, et al. · Clinical & Translational Oncology · 6
PDF
Biomarker-integrated study of single agent targeting molecular alterations of PI3KCA, MET, ALK, ROS1, KRAS, NRAS or BRAF in advanced NSCLC: Phase 2 umbrella trial in China (CTONG1505)
2018 · Q. Zhou, X.-C. Zhang, et al. · Annals of Oncology · 4
659O Molecular diagnosis and management of leptomeningeal metastases with evolving therapeutic paradigm in advanced lung cancer
2025 · M. Zheng, H. Tu, et al. · Annals of Oncology · 1
P1.06B.14 Optimal Cut-Off with NGS for Metamplification Andclinical Relevance to MET Inhibitor in Non-Small-Cell Lung Cancer
2024 · S.-Y.M. Liu, Z. Xie, et al. · Journal of Thoracic Oncology · 1
PDF
WS02.18 Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study
2023 · M.-M. Zheng, L.-B. Tang, et al. · Journal of Thoracic Oncology · 1
PDF
WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
2023 · S.-Y.M. Liu, J.-Y. Deng, et al. · Journal of Thoracic Oncology · 1
PDF
EP08.01-085 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
2022 · S.-Y. Liu, Q. Zhou, et al. · Journal of Thoracic Oncology · 1
PDF
59P Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN IHC as a means for sample quality screening
2016 · X.-C. Zhang, C. Sun, et al. · Annals of Oncology · 1
PDF
P1.11.05 Efficacy and Multi-Omics Insights of Immune Checkpoint Inhibitors in NSCLC With Leptomeningeal Metastasis
2025 · L-B.B. Tang, Y-S. Li, et al. · Journal of Thoracic Oncology
P2.08.35 PD-L1 as a Predictive Biomarker in EGFR-Mutated Non-Small Cell Lung Cancer With Neoadjuvant Immunochemotherapy
2025 · Y-F. Qi, Z-B. Qiu, et al. · Journal of Thoracic Oncology
WITHDRAWN: 1970P NGS utilization in dynamic monitoring and identifying resistance mechanism for later-line osimertinib treatment and outcomes in patients with advanced NSCLC: Results from the ADELOS study
2025 · S-Y. Liu, X-C. Zhang, et al. · Annals of Oncology
2057eP Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed KRASmSTK11mTP53m tumors were highly immune cold with a worse survival outcome
2025 · X-C. Zhang, Y. Chen, et al. · Annals of Oncology
MA07.08 Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC
2024 · M.-M. Zheng, S.-H. Lin, et al. · Journal of Thoracic Oncology
PDF
P1.23-09 Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study
2023 · M.-M. Zheng, L.-B. Tang, et al. · Journal of Thoracic Oncology
PDF
P2.12-08 Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations
2023 · G.-L. Jie, M.-M. Zheng, et al. · Journal of Thoracic Oncology
PDF
P2.06-07 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
2023 · S.-Y.M. Liu, J.-Y. Deng, et al. · Journal of Thoracic Oncology
PDF
EP12.01-39 Therapeutic or Prophylactic Targeting C797S in EGFR Mutant Lung Adenocarcinoma
2023 · X.-H. Guan, C.-D. Weng, et al. · Journal of Thoracic Oncology
PDF
1266P Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets
2021 · H-Y. Tu, Y-S. Li, et al. · Annals of Oncology
Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells
2017 · Y.-S. Li, B.-Y. Jiang, et al. · Annals of Oncology
PDF
439O Tracking spatiotemporal T790M heterogeneity in patients with EGFR-mutant advanced NSCLC after acquired resistance to EGFR TKIs
2016 · Y.-C. Zhang, C. Pi, et al. · Annals of Oncology
PDF
454P Efficacy of crizotinib in NSCLC with concomitant ALK fusion and c-MET overexpression
2016 · R-L. Chen, N-N. Lou, et al. · Annals of Oncology
454P Efficacy of crizotinib in NSCLC with concomitant ALK fusion and c-MET overexpression
2016 · R.-L. Chen, N.-N. Lou, et al. · Annals of Oncology
PDF
154P: Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
2016 · H.-F. Gao, Y.-L. Wu, et al. · Journal of Thoracic Oncology
PDF
Works count: 28
Citation count: 89
H-index: 4
I10-index: 1
Year
Topic
Type